News about Clinical Trials

Medtronic Hugo Robotic System Shows Success in Hernia Repair

Medtronic Hugo Robotic System Shows Success in Hernia Repair

Medtronic’s Enable Hernia Repair study marks the first IDE clinical trial in the US for robotic-assisted hernia surgery, evaluating the Hugo RAS system in inguinal and ventral procedures.

Clinical Trials | 06/09/2025 | By Dineshwori 125

Senhwa Biosciences Secures US FDA Nod to Advance Pidnarulex Trial for MYC-Driven B-Cell Lymphoma

Senhwa Biosciences Secures US FDA Nod to Advance Pidnarulex Trial for MYC-Driven B-Cell Lymphoma

Senhwa Biosciences has received FDA clearance to begin a Phase 1b/2 trial of its novel MYC-targeting drug candidate Pidnarulex (CX-5461) in patients with B-cell lymphoma, marking a potential breakthrough in precision oncology.

Clinical Trials | 06/09/2025 | By Mrinmoy Dey

BioNTech and Duality Biologics reach major breakthrough in breast cancer trial

BioNTech and Duality Biologics reach major breakthrough in breast cancer trial

BioNTech and Duality Biologics have announced a significant advance in cancer drug development with the successful outcome of a Phase III trial for their investigational therapy BNT323, also known as trastuzumab pamirtecan.

Clinical Trials | 06/09/2025 | By Darshana

Sanofi's Amlitelimab Achieves Key Milestone in Phase-III Trial for Atopic Dermatitis

Sanofi's Amlitelimab Achieves Key Milestone in Phase-III Trial for Atopic Dermatitis

Sanofi’s amlitelimab demonstrates sustained efficacy and improved disease outcomes, highlighting the potential to reshape the treatment for atopic dermatitis.

Clinical Trials | 04/09/2025 | By Dineshwori 105

Julius Clinical Strengthens CNS and Cardiometabolic Expertise, Adds Operations in Spain and Germany

Julius Clinical Strengthens CNS and Cardiometabolic Expertise, Adds Operations in Spain and Germany

Julius Clinical has reported strong Q2 2025 growth in CNS and Cardiometabolic bookings, driven by its merger with Peachtree BioResearch Solutions and expanded operations in Spain and Germany.

Clinical Trials | 04/09/2025 | By Mrinmoy Dey

Onco3R Therapeutics Secures Approval to Launch First-in-Human Trial of SIK3 Inhibitor O3R-5671

Onco3R Therapeutics Secures Approval to Launch First-in-Human Trial of SIK3 Inhibitor O3R-5671

Onco3R Therapeutics is expected to start enrolling subjects for the first-in-human trial of SIK3 inhibitor O3R-5671 over the coming weeks, with dosing of the first subject anticipated later in September.

Clinical Trials | 04/09/2025 | By Dineshwori 100

India to Reform New Drugs and Clinical Trials Rules, Halve Processing Time for Test Licences

India to Reform New Drugs and Clinical Trials Rules, Halve Processing Time for Test Licences

By amending the New Drugs and Clinical Trials (NDCT) Rules, 2019, the Indian government aims to simplify the requirements and procedures for obtaining test licences and for submitting applications related to Bioavailability/Bioequivalence (BA/BE) studies.

Clinical Trials | 04/09/2025 | By Dineshwori

SK bioscience Files IND for Global Phase 3 Trial of Two-Dose Varicella Vaccine

SK bioscience Files IND for Global Phase 3 Trial of Two-Dose Varicella Vaccine

SK bioscience's Phase 3 clinical trial of SKYVaricella aims to evaluate the immunogenicity and safety of the 2-shot varicella vaccine in roughly 800 children aged 12 months to 12 years, with completion targeted by 2027.

Clinical Trials | 02/09/2025 | By Dineshwori

Foresight Diagnostics Resolves Litigation with Roche, Grants Limited License for PhasED-Seq in Lymphoma

Foresight Diagnostics Resolves Litigation with Roche, Grants Limited License for PhasED-Seq in Lymphoma

Foresight Diagnostics, a privately held cancer diagnostics company, has entered into a limited licensing agreement with Roche Molecular Systems and Roche Sequencing Systems, resolving ongoing litigation between the parties. As part of the resolution, all claims against Foresight, its founders, and Stanford University have been dismissed with prejudice.

Clinical Trials | 01/09/2025 | By Darshana 112

AstraZeneca's Baxdrostat Achieves Significant Blood Pressure Reduction in Phase-III Study

AstraZeneca's Baxdrostat Achieves Significant Blood Pressure Reduction in Phase-III Study

The BaxHTN phase-III trial showed Baxdrostat, an investigational drug developed by AstraZeneca, significantly lowered systolic blood pressure in patients with hard-to-control hypertension, achieving both statistical and clinical relevance.

Clinical Trials | 01/09/2025 | By Dineshwori

 
 

 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members